Incyte Genomics Inc (NASDAQ: INCY) has lately had an upward price trend, gaining 19.6% in three months and 7% in one week with a 0.9% increase after the last earnings report. The company presented late-breaking Phase 3 results for Retifanlimab (Zynyz®) and preliminary data from the Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024. The Impact of Retifanlimab on progression-free survival in patients with Squamous Cell Anal Carcinoma (SCAC) was emphasized as main data. The Q1 earnings were slightly under expectations, causing concerns. However, notable was its CDK2 Inhibitor INCB123667 showing considerable clinical activity in patients with advanced solid tumors, especially ovarian cancer. Despite these positive updates, the stock fell 29.6% in the year to date. The company also highlights oncology data at the 2024 ASCO Annual Meeting and EHA2024 Congress.
Incyte Genomics INCY News Analytics from Tue, 07 Nov 2000 08:00:00 GMT to Sun, 15 Sep 2024 15:39:25 GMT -
Rating 1
- Innovation 6
- Information 7
- Rumor -3
